Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain

Medical Mycology

Volumn 48, Issue 7, 2010, Pages 942-948

  Guinea, Jesús ^a,b   Hagen, Ferry ^c,d   Peláez, Teresa ^a,b   Boekhout, Teun ^c,d   Tahoune, Hicham ^a   Torres Narbona, Marta ^a   Bouza, Emilio ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cryptococcus neoformans; Genotyping; Isavuconazole; Mating; Serotyping

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ISAVUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MATING TYPE; MINIMUM INHIBITORY CONCENTRATION; SEROTYPING; SPAIN;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTIFUNGAL AGENTS; COMORBIDITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FEMALE; HIV INFECTIONS; HOSPITALS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICROBIAL SENSITIVITY TESTS; SEROTYPING; SPAIN; TRIAZOLES;

FILOBASIDIELLA NEOFORMANS;

EID: 77957735262     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693781003690067     Document Type: Article

References (31)

1. Singh N, Alexander BD, Lortholary O, et al. Pulmonary cryptococ-cosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46: e12-18.
2. Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infec-tion: characteristics and epidemiology of cases identif ed in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 2006; 43: 1077-1080.
3. Kwon-Chung J, Boekhout T, Fell JW, Diaz M. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacil-lisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 2002; 51: 804-806.
4. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 2006; 6: 574-587.
5. Bovers M, Hagen F, Boekhout T. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol 2008; 25: S4-12.
6. Bovers M, Hagen F, Kuramae EE, et al. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res 2006; 6: 599-607.
7. Boekhout T, Theelen B, Diaz M, et al. Hybrid genotypes in the path-ogenic yeast Cryptococcus neoformans. Microbiology 2001; 147: 891-907.
8. Bovers M, Hagen F, Kuramae EE, et al. AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis 2008; 14: 1105-1108.
9. Barreto de Oliveira MT, Boekhout T, Theelen B, et al. Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J Clin Microbiol 2004; 42: 1356-1359.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard CLSI Document M27-A3. Clinical and Laboratory Stan-dards Institute, Wayne, PA, 2008.
11. Viviani MA, Cogliati M, Esposto MC, et al. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM sur-vey of cryptococcosis in Europe. FEMS Yeast Res 2006; 6: 614-619.
12. Haynes KA, Sullivan DJ, Coleman DC, et al. Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococ-cosis and reinfection with novel strains in recurrent infection dem-onstrated by random amplif cation of polymorphic DNA and DNA f ngerprinting. J Clin Microbiol 1995; 33: 99-102.
13. Fries BC, Chen F, Currie BP, Casadevall A. Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol 1996; 34: 1531-1534.
14. Thompson GR, 3rd, Wiederhold NP, Fothergill AW, et al. Antifungal sus-ceptibilities among different serotypes of Cryptococcus gattii and Crypto-coccus neoformans. Antimicrob Agents Chemother 2009; 53: 309-311.
15. Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neo-formans var. grubii and Cryptococcus gattii to f ve antifungal drugs. Mycoses 2006; 49:324-330.
16. Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R. Antifungal susceptibility of Cryptococcus neoformans and Cryp-tococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 2007; 60: 312-316.
17. Chen YC, Chang SC, Shih CC, et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 2000; 36: 175-183.
18. Dannaoui E, Abdul M, Arpin M, et al. Results obtained with vari-ous antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464-2470.
19. Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clini-cal isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998; 36: 2817-2822.
20. Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of f ucon-azole MICs with clinical outcome in cryptococcal infection. Antimi-crob Agents Chemother 2000; 44: 1544-1548.
21. Witt MD, Lewis RJ, Larsen RA, et al. Identif cation of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with f uconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322-328.
22. Davey KG, Johnson EM, Holmes AD, Szekely A, Warnock DW. In vitro susceptibility of Cryptococcus neoformans isolates to f ucon-azole and itraconazole. J Antimicrob Chemother 1998; 42: 217-220.
23. Brandt ME, Pfaller MA, Hajjeh RA, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45:3065-3069.
24. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifun-gal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167.
25. Sar B, Monchy D, Vann M, et al. Increasing in vitro resistance to f uconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004; 54: 563-565.
26. Perkins A, Gómez-López A, Mellado E, Rodríguez- Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Anti-microb Chemother 2005; 56: 1144-1147.
27. Torres-Rodríguez JM, Alvarado-Ramírez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, vori-conazole and f uconazole for Cryptococcus neoformans and Crypto-coccus gattii. J Antimicrob Chemother 2008; 62: 205-206.
28. Illnait-Zaragozi MT, Mart í nez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52: 1580-1582.
29. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voricon-azole, posaconazole, and f uconazole against 4, 169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-205.
30. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10. 5-year analysis of susceptibilities of noncandidal yeast species to f uconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-123.
31. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, f uconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015.